| Year |
Citation |
Score |
| 2018 |
Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate. PMID 29851094 DOI: 10.1002/Pros.23657 |
0.878 |
|
| 2017 |
Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. The Journal of Pathology. PMID 28888037 DOI: 10.1002/Path.4980 |
0.816 |
|
| 2016 |
Valle JABD, Zheng Q, Rubenstein M, Meeker AK, Heaphy CM, Hubbard G, Bieberich CJ, Yegnasubramanian S, Esopi D, Wheelan SJ, Marzo AMD. Abstract LB-160: Human telomerase RNA component (hTR/TERC) is consistently overexpressed in prostate cancer, required for cell proliferation and is positively regulated by MYC Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-160 |
0.826 |
|
| 2016 |
Borodovsky A, McQuiston TJ, Dougherty B, Ahmed A, Whitston D, Stetson D, Hubbard GK, Challberg SS, Pollok BA, D’Cruz CM. Abstract 641: Use of conditional reprogramming to develop and characterize cell cultures from patient-derived xenograft (PDX) models of human lung and ovarian cancer Cancer Research. 76: 641-641. DOI: 10.1158/1538-7445.Am2016-641 |
0.361 |
|
| 2015 |
Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Research. PMID 26554830 DOI: 10.1158/0008-5472.Can-14-3280 |
0.346 |
|
| 2015 |
Hubbard GK, Yu S, Shinohara DB, Vaghasia A, Nelson WG, Yegnasubramanian S, Marzo AMD, Sfanos KS. Abstract 5021: Histopathologic and gene expression analysis in mouse models of long-term chronic prostatic inflammation using human prostate cancer-derived bacterial isolates Immunology. 75: 5021-5021. DOI: 10.1158/1538-7445.Am2015-5021 |
0.75 |
|
| 2013 |
Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks J, Bianchi-Frias D, Nelson PS, Yegnasubramanian S, Marzo AMD, Bieberich CJ. Abstract 1086: MYC overexpression combined with Pten loss generates genomic instability and rapid metastasis in a new mouse model of lethal prostate adenocarcinoma. Cancer Research. 73: 1086-1086. DOI: 10.1158/1538-7445.Am2013-1086 |
0.763 |
|
| 2010 |
Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. Plos One. 5: e9427. PMID 20195545 DOI: 10.1371/Journal.Pone.0009427 |
0.826 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Research. 73: 5810-20. PMID 23928995 DOI: 10.1158/0008-5472.Can-13-0523 |
0.255 |
|
| 2011 |
Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Research : Bcr. 13: R89. PMID 21923922 DOI: 10.1186/Bcr2946 |
0.195 |
|
| 2015 |
Heltemes-Harris LM, Larson JD, Starr TK, Hubbard GK, Sarver AL, Largaespada DA, Farrar MA. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia. Oncogene. PMID 26500062 DOI: 10.1038/Onc.2015.405 |
0.171 |
|
| Hide low-probability matches. |